GENEART Supports the UK HIV Vaccine Consortium in Developing a DNA Vaccine Candidate against HIV
News Jun 19, 2009
GENEART AG announces being awarded a contract for the design and production of two DNA vaccine candidates against HIV by the UK HVC. The genes (blueprints for virus proteins), optimized and customized by GENEART, are to be used as basis for clinical studies.
Two gene constructs, developed by GENEART in cooperation with the Institute of Medical Microbiology and Hygiene at the University of Regensburg, are currently being evaluated at Clinical Phase I/II under the umbrella of the European research syndicate EuroVacc, since Phase I results were promising.
The genes ordered by the UK HVC are based on a different HIV isolate but rest on the same concept as the gene constructs already used in clinical studies. Blueprints of selected proteins of the HIV virus are modified using GENEART's proprietary GeneOptimizer® Software such that they can be produced with maximal yield and therefore triggering an optimal immune response but at the same time losing their toxic capacity, thus contributing to an increased safety profile.
GENEART will not only provide the respective genes, but will in addition - as an extension of the value chain - analyze and ensure the producibility of the resulting proteins in cell cultures (Expression Proof).
The UK HVC does not only benefit from the rational design of the respective genes or virus proteins but also from a production in accordance with DIN EN ISO 9001:2000 as well as a documentation of the production process. Thereby, GENEART provides ideal conditions for the subsequent approval process.
"This order shows once again how we established both gene design and gene synthesis as the gold standard for the development of vaccines. Customers benefit from optimal properties with respect to immune response and safety due to maximal design flexibility during the development of vaccines", said Prof. Dr. Ralf Wagner, CEO and CSO of GENEART.
Quotient Sciences Acquires Pharmaterials, a UK-based Contract Development and Manufacturing OrganizationNews
Quotient Sciences, the drug development services organization, announces it has acquired Pharmaterials, a contract development and manufacturing organization (CDMO) based in Reading, U.K..READ MORE
Researchers Discover Mutation That Appears to Protect Against Multiple Aspects of Biological AgingNews
The first genetic mutation that appears to protect against multiple aspects of biological aging in humans has been discovered in an extended family of Old Order Amish living in the vicinity of Berne, Indiana, report Northwestern Medicine scientists.READ MORE
Researchers Find a Way to Separate Side Effects of Opioid Drugs Reducing RiskNews
Scientists have discovered a way to separate these two effects -- pain relief and breathing, opening a window of opportunity to make effective pain medications without the risk of respiratory failure.READ MORE